HOLX
$75.05
Hologic, Inc.
Recent News
How The Hologic (HOLX) Story Is Shifting Toward A Deal Driven Wait And See Trade
Hologic’s latest update keeps its fair value estimate steady at about US$76.60 per share, signaling no change to the headline price target in current analyst models. That stability comes as research shifts the stock toward a wait and see idea, with the pending buyout of up to US$79 per share now setting the tone for how many analysts frame upside and risk. As you read on, you will see how to track this evolving, deal-driven narrative and what it could mean for your own view on...
What Drives Hologic's GYN Surgical Strength in a Competitive Market?
HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.